Pharmacy Department, Faculty of Science, National University of Singapore, Singapore
MyCRSAnnual General Meeting and Award for best poster presentation
Networking Lunch *
Poster Presentation Session
We encourage research students, to present a poster on the work in the fields of controlled-release drug delivery systems and medical nanotechnology. All student poster presenters will give a “Poster on the Podium” short 2 minute/one slide oral presentation in the morning to compete for the poster prize of RM 100. The poster will also be evaluated by a panel of judges subsequently during theTea Break/Poster Session.
To participate in the poster presentation session, one must:
1.Prepare a poster abstract according to the following format:
a.Use Arial font size 12 throughout the abstract.
b.Poster title should be bold.
c.List all authors and use superscript numbersto identify author’s affiliation.
d.Abstract of not more than 200 words in double spacing.
2.Submit your poster abstract limited to a single page as Microsoft Word and pdf format, and mailed email@example.comJuly 2017.
The abstracts will be peer reviewed. The Program Committee reserves the right to reject abstracts that do not meet the minimum technical/scientificrequirements. All the applicants will be informed on decision of the acceptance for poster presentation by3rdAugust 2017.
Instruction for poster preparation:
1.Maximum poster dimensions:A0 (84.1 cm width x 118.9 cm height or 33.1 inches width x 46.8 inches height, portraitorientation)
2.Font size for the poster title: 57 (0.8” or 2 cm height).
3.General font size for the poster content: 27 (3/8” or 0.95 cm).
i.Title: The poster title must match to that of abstract.
ii.Authors: All contributing authors and their affiliation(s) must be stated
iii.Introduction and Aims: A brief introduction on the background and the main aims of the study must be provided.
iv.Methods: The key methodologies employed in the study must be outlined.
v.Results and discussion: The results and discussion must be presented in a concise and chronological manner. The use of properly labelled figures, graphs or tables are imperative.
vii.References: Key references must be given.
5.Poster board will be set up at the ground floor hallway of the High Impact Research building. All posters are required to be displayed on the assigned boards before 9:00 am on 8thAugust 2017 and removed before 2.00 pm on the same day.
6.Poster category and number: Abstractaccepted for the poster presentation will be given an identity number. Please put up your poster on the poster board that bears the said identity number.
Milk as an enabling formulation in low economic pediatric applications
Milk is a fascinating material. It has been well studied with respect to solubility of poorly water soluble drugs, but the interaction of the drug with formulation components during digestion has not been previously studied. We have been investigating the interaction of a fixed dose combination of drugs for a single dose cure for malaria, and have developed new insights into behavior of the drugs when formulated in milk and milk-like materials in vitro, that is informing clinical exposure and formulation selection.
Prof. Ben Boydis a colloid and physical chemist with PhD from the University of Melbourne (1999). After industry experience in the explosives and pharmaceutical industries, he commenced an academic position at Monash Institute of Pharmaceutical Sciences (MIPS) and currently holds an ARC Future Fellowship for the discovery and development of light activated drug delivery systems. His research group focusses on colloidal and structural aspects of lipids, lipid self-assembly and pharmaceutical systems, focused on controlling materials at the colloidal scale for delivery in pharma and other fields. His group is also active in developing new synchrotron-based characterization approaches for lipid and solid state systems. He was the recipient of the American Association of Pharmaceutical Scientists 2011 Lipid-based Drug Delivery Award Outstanding Research Award. He is Past President of the Australian Chapter of the Controlled Release Society (CRS), Past Secretary of Global CRS, and is Past Secretary of the Colloid and Surface Science Division of the Royal Australian Chemical Society. He is an active member of the Australian Colloid and Interface Society. He serves on the editorial boards of several journals including Associate Editor for Drug Delivery and Translational Research, Journal of Pharmaceutical Sciences and Journal of Colloid and Interface Science.
Delivery of natural products through liposomal nanovesicles attenuates cardiac dysfunction after myocardial infarction.
Adverse left ventricular remodeling can be evaluated as a reduction in ejection fraction after myocardial infarction (MI). This leads to heart failure and is a main determinant of mortality and morbidity after MI. To improve remodeling, anti-inflammatory compounds have shown promise. Berberine has ascribed anti-inflammatory, anti-oxidative, and cardioprotective properties. However, the poor solubility in aqueous buffers and a short half-life in the circulation have been impeding the usage of this natural product. We hypothesize that encapsulation of berberine into long circulating liposomes could improve its therapeutic availability and efficacy to protect cardiac function in vivo.
Assoc. Prof.GiorgiaPastorinreceived her MSc degree in Pharmaceutical Chemistry and Technology in 2000 and her Ph.D. in 2004 from the University of Trieste (Italy), working on adenosine receptors’ antagonists. She spent 2 years as apostDocat CNRS in Strasbourg (France) where she acquired some skills in drug delivery. She joined the National University of Singapore in June 2006, as Assistant Professor in the Department of Pharmacy-Faculty of Science. She was promoted to Associate Professor in 2011, Assistant Head in 2014 and she is currently Deputy Head (Research)in the same Department.
Her research interests focus on Drug Delivery, through the exploitation of synthetic and cell-derived nanoparticles, for a variety of potential therapeutic applications. For the work performed by herBioNanoTechnologygroup in NUS, she received the Young Scientist Award in 2016.